|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)显示文摘Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC. | Hui-Chuan Sun Jian Zhou Zheng Wang Xiufeng Liu Qing Xie Weidong Jia Ming Zhao Xinyu Bi Gong Li Xueli Bai Yuan Ji Li Xu Xiao-Dong Zhu Dousheng Bai Yajin Chen Yongjun Chen Chaoliu Dai Rongping Guo Wenzhi Guo Chunyi Hao Tao Huang Zhiyong Huang Deyu Li Gang Li Tao Li Xiangcheng Li Guangming Li Xiao Liang Jingfeng Liu Fubao Liu Shichun Lu Zheng Lu Weifu Lv Yilei Mao Guoliang Shao Yinghong Shi Tianqiang Song Guang Tan Yunqiang Tang Kaishan Tao Chidan Wan Guangyi Wang Lu Wang Shunxiang Wang Tianfu Wen Baocai Xing Bangde Xiang Sheng Yan Dinghua Yang Guowen Yin Tao Yin Zhenyu Yin Zhengping Yu Bixiang Zhang Jialin Zhang Shuijun Zhang Ti Zhang Yamin Zhang Yubao Zhang Aibin Zhang Haitao Zhao Ledu Zhou Wu Zhang Zhenyu Zhu Shukui Qin Feng Shen Xiujun Cai Gaojun Teng Jianqiang Cai Minshan Chen Qiang Li Lianxin Liu Weilin Wang Tingbo Liang Jiahong Dong Xiaoping Chen Xuehao Wang Shusen Zheng Jia Fan 无 | 2022 | Hepatobiliary Surgery and Nutrition2022，11，2： | 4 |
| 2 | Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions—A comparison of conventional ultrasound and contrast-enhanced CT显示文摘 | Zhihui Fan Ying Li Kun Yan Wei Wu Shanshan Yin Wei Yang Baocai Xing Xiaoting Li Xiaopeng Zhang | 2013 | European Journal of Radiology2013，，： | 1 |
| 3 | National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China(English version)显示文摘Contents 1.Introduction 2.Diagnostic techniques and applications 2.1 Risk factors for pancreatic cancer 2.2 Clinical manifestations 2.3 Physical examination 2.4 Radiological examination 2.4.1 Ultrasound 2.4.2 Computed tomography(CT)2.4.3 Magnetic resonance imaging(MRI)and magnetic resonance cholangiopancreatography(MRCP)2.4.4 Positron emission tomography-CT(PET-CT)。 | 无 Baocai Xing Kemin Jin | 2022 | Chinese Journal of Cancer Research2022，34，3： | 1 |
| 4 | 1B50-1, a mAb Raised against Recurrent Tumor Cells, Targets Liver Tumor-Initiating Cells by Binding to the Calcium Channel α2δ1 Subunit显示文摘 | Wei Zhao Limin Wang Haibo Han Kemin Jin Na Lin Ting Guo Yangde Chen Heping Cheng Fengmin Lu Weigang Fang Yu Wang Baocai Xing Zhiqian Zhang | 2013 | Cancer Cell2013，，： | 1 |
| 5 | 1B50-1, a mAb Raised against Recurrent Tumor Cells, Targets Liver Tumor-Initiating Cells by Binding to the Calcium Channel α2δ1 Subunit显示文摘 | Wei Zhao Limin Wang Haibo Han Kemin Jin Na Lin Ting Guo Yangde Chen Heping Cheng Fengmin Lu Weigang Fang Yu Wang Baocai Xing Zhiqian Zhang | 2013 | Cancer Cell2013，，4： | 1 |
| 6 | Does not hUTP14a promoter form a regulation feedback loop with P53?显示文摘Objective: We previously found that hUTP14a binds P53 and promotes P53 degradation. However, if hUTP14a is a downstream gene of P53 remains to be determined. This study aimed to identify the promoter of hUTP14a and investigate if hUTP14a is regulated by P53.Methods: The hUTP14a promoter region was cloned into pGL3-Basic-luciferase reporter plasmid to get pGL3-hUTP14a-luc. The reporter plasmid was transfected into 293T cells and luciferase activity was evaluated by the Dual-Luciferase Reporter Assay System. Putative transcription factors were identified through searching MatInspector Professional and Algorismica i Genetica databases. Either pGL3-hUTP14aluc or p21 promoter reporter plasmid was co-transfected with increasing dose of p53 plasmid, and luciferase activity was evaluated. A series of deletion constructs of pGL3-hUTP14a-luc were constructed and minimal promoter region of hUTP14a was determined. Differences of the luciferase activities between different groups were assessed by statistical analysis.Results: The hUTP14a gene promoter reporter construct was correctly cloned and was demonstrated to possess promoter activity. The transcription of hUTP14a was not regulated by P53. The minimal promoter region of hUTP14a gene is located between-203 to-100 of the transcription initiation site.Conclusion: Unlike other P53-interacting proteins such as MDM2, Pirh2 and Cop I which promote P53 degradation and whose transcriptions are regulated by P53, does not hUTP14a transcription form a regulation feedback loop with P53. | Jingyi Zhang Yafei Guo Xiaojuan Du Baocai Xing | 2014 | Chinese Journal of Cancer Research2014，26，2： | 0 |
| 7 | Comments on National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China(English version)显示文摘Pancreatic cancer is a serious threat to human health,and the incidence is on the rise.Due to lack of obvious symptoms in early stage,it is often diagnosed in late stage.Its biological behavior is poor,and up to now,surgery and medical treatment have not achieved optimal effect. | Kemin Jin Baocai Xing | 2022 | Chinese Journal of Cancer Research2022，34，6： | 0 |
| 8 | Surgical decision-making: can patients benefit?显示文摘What is surgery?It is difficult for us to have time to think about this broad question in our busy,day-to-day work.In some“super hospitals”,patient admission and surgical operation have even become an“assembly-line”job.When a patient successfully recovers from an operation without any postoperative complications,we may be silently proud of our surgical skills. | Ming Liu Baocai Xing | 2021 | Hepatobiliary Surgery and Nutrition2021，10，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员